745 related articles for article (PubMed ID: 25750269)
41. Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
McMahon DJ; Gleeson JP; O'Reilly S; Bambury RM
Med Oncol; 2022 Jun; 39(9):129. PubMed ID: 35716200
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
43. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
44. Current status of immunotherapy and gene therapy for high-grade gliomas.
Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
[TBL] [Abstract][Full Text] [Related]
45. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
[TBL] [Abstract][Full Text] [Related]
46. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
47. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.
Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K
Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743
[TBL] [Abstract][Full Text] [Related]
48. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Corso CD; Bindra RS
Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
[TBL] [Abstract][Full Text] [Related]
49. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
[TBL] [Abstract][Full Text] [Related]
50. Promising vaccines for treating glioblastoma.
Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
[TBL] [Abstract][Full Text] [Related]
51. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
52. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
53. Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.
Ji N; Zhang Y; Liu Y; Xie J; Wang Y; Hao S; Gao Z
JCI Insight; 2018 May; 3(10):. PubMed ID: 29769450
[TBL] [Abstract][Full Text] [Related]
54. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
[TBL] [Abstract][Full Text] [Related]
55. [Current status and prospect in the treatment of glioblastoma].
Jiang HH; Lin S
Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):70-74. PubMed ID: 31902174
[TBL] [Abstract][Full Text] [Related]
56. Glioblastoma multiforme: Pathogenesis and treatment.
Alifieris C; Trafalis DT
Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
[TBL] [Abstract][Full Text] [Related]
57. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Del Vecchio CA; Li G; Wong AJ
Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
[TBL] [Abstract][Full Text] [Related]
58. Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.
dos Santos MA; Pignon JP; Blanchard P; Lefeuvre D; Levy A; Touat M; Louvel G; Dhermain F; Soria JC; Deutsch E; Le Teuff G
J Neurooncol; 2015 Jun; 123(2):307-14. PubMed ID: 25975195
[TBL] [Abstract][Full Text] [Related]
59. Radiation and Immunotherapy in High-grade Gliomas: Where Do We Stand?
Reznik E; Smith AW; Taube S; Mann J; Yondorf MZ; Parashar B; Wernicke AG
Am J Clin Oncol; 2018 Feb; 41(2):197-212. PubMed ID: 28906259
[TBL] [Abstract][Full Text] [Related]
60. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
